GlassScriptPhysician profile
Elizabeth E Richwine
NPI 1548383292
$8,673.40
in general payments reported to CMS, 2019-2025
30 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $737 · 2021: $808 · 2022: $1,070 · 2023: $1,029 · 2024: $2,147 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,928 · Education: $86.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.17 |
| Education | $86.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,881.73 | 2019-2025 | |
| Abbvie INC. | $1,811.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,454.84 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $790.13 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $561.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.97 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $225.27 | 2019-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $169.36 | 2023-2025 | Zoryve |
| Incyte Corporation | $165.72 | 2021-2023 | Opzelura |
| Ucb, INC. | $156.51 | 2019-2024 | Bimzelx |
| Lilly USA, LLC | $156.39 | 2019-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $142.02 | 2020-2025 | Ilumya |
| Dermavant Sciences, INC. | $123.02 | 2023-2024 | Vtama |
| Amgen INC. | $122.44 | 2023-2024 | Otezla |
| Galderma Laboratories, L.P. | $117.61 | 2019-2025 | Nemluvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $112.27 | 2019-2025 | |
| Botanix Sb INC | $48.21 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $44.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.56 | 2023-2024 | Spevigo |
| Biofrontera INC. | $38.48 | 2021 | |
| Mayne Pharma Commercial LLC | $38.15 | 2019-2025 | |
| Organon LLC | $33.65 | 2025 | Vtama |
| Kerecis Limited | $27.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Paratek Pharmaceuticals, INC. | $26.64 | 2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $24.26 | 2021 | |
| Verrica Pharmaceuticals INC. | $20.44 | 2025 | Ycanth |
| Dermira, INC. | $19.59 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.41 | 2025 | Jublia |
| Fresenius Kabi USA, LLC | $16.05 | 2024 | Idacio |
| Almirall LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Richwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.